Davinderpreet Mangat, Pamela Spicer, Jessica Merrill, and Catherine Kelly discuss the approval of Aduhelm in Alzheimer’s disease.
Topics covered include:
• Drug development and approval - 01:45
• Pricing and commercial potential - 15:12
• National reimbursement processes - 30:55
Supporting links:
• Datamonitor’s Alzheimer’s Disease Analysis report - https://service.datamonitorhealthcare.com/hkc/disease/central-nervous-system/neurology/alzheimers-disease/disease-analysis/article209751.ece
• Biogen: Aduhelm’s Price Is Part Of Alzheimer’s ‘Evolution’ - https://scrip.pharmaintelligence.informa.com/SC144754/Biogen-Aduhelm-Price-Is-Part-Of-Alzheimers-Evolution
• Medicare Coverage Analysis Of Alzheimer’s Drugs Begins With Focus On Outcomes, Patient Eligibility - https://pink.pharmaintelligence.informa.com/PS144631/Medicare-Coverage-Analysis-Of-Alzheimers-Drugs-Begins-With-Focus-On-Outcomes-Patient-Eligibility
Other platforms:
• Apple Podcasts - https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836
• Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz
• TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/
• Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67
